BioSpace News Archive

American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on July 22, 2020, it had filed with the US Patent and Trademark Office (“USPTO”) a new patent for the treatment of Major Depressive Disorder

Meridian is pleased to announce the appointment of James Kiamos as the President and Chief Executive Officer for Centene’s Illinois market including Meridian in Illinois and YouthCare program effective beginning August 24, 2020.

Exo (pronounced “echo”), a pioneering health information and devices company, closed a $40 million Series B+ funding round that will fund research and product development on a revolutionary handheld medical device and cloud-based workflow software platform.

Through fostering partnerships with large organizations in the U.S. healthcare system, newly appointed General Manager Ryan Hovey will spearhead the company’s B2B commercial efforts

Diomics, a San Diego-based biotech company, today announced that it is currently developing the Diocheck™ Antibody Indicator, which provides a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 over an extended period of time.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced certain shareholders have confirmed the early exercise of approximately 7.1 million common stock warrants since July 1, 2020 for which ENDRA accepted reduced exercise prices

NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Company has concluded advanced exploratory talks with the European Commission to supply 80 million doses of mRNA-1273,

Fibronostics, a global company providing non-invasive, algorithmic diagnostics for NASH patients, announced today that it has secured $8 million in series A funding.

Researchers have modified a derivative of a plant toxin and linked it to a nanocarrier to create a powerful new therapeutic for childhood tumors. The new drug and its ability to eliminate chemoresistant tumors in mice is described in a new study published in Cancer Research, a journal of the American Association for Cancer Rese